Tophi are a symptom of gout. They are large, hardened masses of uric acid crystals within and around the joints. These masses can cause pain, joint deformity, and limited range of motion.

Other symptoms can include: Decreased range of motion Redness Swelling in finger joints Warm or hot skin around the affected ...

Her general practitioner diagnosed gouty arthritis because of a high serum uric-acid level (600 µmol/l; normal range 270–380 µmol/l) coexistent with tophi in her hands, and initiated ...

MDedge News, December 15, 2022 ACR 2022 Intensive Gout Treatment Meets Urate Goal, Lowers Tophi Burden The second randomized trial of therapy to intensively lower urate for patients with gout ...

dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the efficacy and safety of a 10, 30, or 60 mg tablet dose of SAP-001. The study enrolled 87 patients from ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial. "We would like to thank the gout community for ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

and dissolve tophi in gout and tophaceous gout patients, today announced that it has dosed the first patient in REDUCE 1, the Company's second pivotal Phase 3 clinical trial evaluating AR882.